A Better Business at a Worse Price: Margin Guide Raised to +75bps and ICOTYDE at 11,000 Patients, but Abiomed Breaks the Cardiovascular Pillar and the Multiple Has Done the Work

Rating Action & Valuation

Downgrading to Hold from Outperform; fair value range raised to $215–245 from $190–220. We have carried Outperform on JNJ since the Q3 2025 upgrade, through three prints that each validated the call. This quarter validates it again on the operating line. We are downgrading anyway, because the argument for owning the stock was never simply that the business is good. It was that the business was good and the market had not paid for it. The market has now paid for it.

The arithmetic is unsentimental. At the $247.02 close the stock trades at 21.1x the FY26 adjusted EPS guide midpoint of $11.68. Our $190–220 range was set at the Q3 2025 upgrade and held through Q1 on a 17–19x framework; applied to the raised guide, that same framework produces $199–222. The stock is 11–24% through it.

We do not think the answer is to hold the multiple static and call the stock expensive, because the earnings quality has genuinely improved. The margin guide moving to +75bps, the $0.18 operational EPS raise, ICOTYDE de-risking the single largest launch variable in the portfolio, INLEXZO doubling, the tax-rate guide coming down, and net debt falling from roughly $33B to $28B are all real. Each argues for paying more than we were willing to pay in October. So we are raising the range to $215–245, or 18.4–21.0x the new midpoint. That is a deliberate re-rate of our own framework, and it is the most constructive valuation we have published on this name.

It still does not get us to Outperform. At $247.02, the midpoint of the raised range implies roughly 7% downside, about 5% after the 2.1% dividend yield. The top of the range implies a total return of roughly +1%. To underwrite Outperform we would have to pay more than 21x for a business guiding to roughly 7% operational sales growth and 7–8% adjusted EPS growth, with the MedTech segment decelerating and its cardiovascular engine gated on data that does not arrive until 2027. We are not willing to do that. A Hold here is not a statement that the compounding stops. It is a statement that at 21x, twelve months of it is already in the price.

Results vs. Consensus

Year-over-year

First half

Revenue assessment. This is the sixth consecutive quarter in which the ex-STELARA lens tells the truth and the headline does not. Worldwide operational growth of +5.6% carries a 460bps STELARA drag, down from 540bps in Q1, and the drag will keep thinning because STELARA is now only 4.5% of Innovative Medicine. There is not much left to lose. The enterprise grew double digits excluding it, and that is the number that describes the run-rate the company exits 2026 with. The revenue beat is also broad rather than concentrated: eight brands grew double digits, oncology grew +16.1%, and neuroscience grew +13.4%. The one soft spot, MedTech, is the one the market traded.

Margin assessment. The 30bps decline is a decisive improvement on Q1's 410bps and it cleared the explicit test we set in April. Both segments compressed only 20bps: Innovative Medicine 42.7% to 42.5%, MedTech 22.2% to 22.0%. But two caveats keep us from calling this resolved. First, MedTech's 22.0% is essentially unchanged from the compressed level we flagged at initiation a year ago, when the segment ran 25.7%; the compression never actually reversed, it just stopped getting worse, and the "MedTech margin recovery" line in our own Q3 2025 upgrade has not shown up in the segment margin. Second, and more important, H1 as a whole ran 212bps below prior year. Management's answer to that is a raised full-year guide, which puts an extraordinary amount of weight on the second half. We size that below.

EPS assessment. $2.90 against ~$2.85 is a real beat and the $0.18 operational raise is a real raise, roughly nine times the size of Q1's. But the composition deserves scrutiny. The reported EPS raise is only $0.13 because currency took back $0.05 as the euro moved from 1.17 to 1.14, and the guide now leans on a lower tax rate and lower net interest expense. What management has genuinely delivered is a portfolio compounding at a double-digit rate underneath a shrinking legacy drag. What it has not yet delivered is the operating leverage; that is an H2 event on the company's own numbers.

Segment Performance — Innovative Medicine ($16.38B, +6.8% operational)

The first $16B quarter in the company's history, delivered through a 760bps STELARA headwind that was 920bps a quarter ago. Excluding STELARA, which is now 4.5% of the segment, the other 96% grew over 14%. Eight brands grew double digits. This is the segment carrying the company, and it is carrying it more comfortably each quarter as the biosimilar math exhausts itself.

Oncology

The strongest franchise in the company and, on management's stated ambition, the strongest in the industry by 2030 at more than $50B. DARZALEX alone did $4.2B at +17.6% with five points of share gain across all lines and nearly eleven points in frontline, which is the number that matters because frontline share compounds into the CARVYKTI, TECVAYLI and TALVEY flywheel behind it. Management's claim that 80% of multiple-myeloma patients receive at least one J&J medicine during their journey is the clearest articulation of why this franchise is defensible: it is not one drug, it is the whole line-of-therapy ladder. TECVAYLI's +46.2% sequential in the U.S. off the DARZALEX FASPRO combination approval is the visible proof.

Assessment: Oncology at +16.1% is doing the work that the STELARA cliff requires, and the new-data cadence this quarter (PROTEUS opening the ASCO plenary, RYBREVANT in head and neck, TALVEY plus DARZALEX at 80%+ progression-free at two years) suggests the growth rate is not near-term-capped. This is the pillar we are most confident in and the one least reflected in the debate about the stock.

Immunology

The segment declined 4.6% and that number is worthless without decomposition. TREMFYA grew 71% to its first $2B quarter and STELARA fell 55.7%; those two facts are the segment. TREMFYA is now the induction share leader in both ulcerative colitis, at 58% of IL-23 inductions, and Crohn's, at over 50%, and it received the structural-damage label expansion in psoriasis and psoriatic arthritis this quarter. The FUSION data in perianal fistulizing Crohn's, the first positive study in that setting in over twenty years, extends the differentiation further into the severe end of a disease affecting roughly a quarter of patients.

Assessment: The bridge management is drawing is explicit and, in our view, credible: over 75% of STELARA's sales were in IBD, TREMFYA leads IBD induction, and there is no structural reason TREMFYA cannot reach or exceed that base. The segment prints negative for another quarter or two on arithmetic. The franchise underneath it is the healthiest it has been.

Neuroscience

The quietest good news in the print. +13.4% operational, with SPRAVATO +40.0% and accelerating sequentially at +24.8%, and CAPLYTA +70.9% with new patient starts up 122% year-over-year and, per management, outpacing the market leader. The schizophrenia relapse-prevention approval this quarter extends CAPLYTA's runway beyond the adjunctive-MDD launch that is currently driving it.

Assessment: CAPLYTA is tracking toward the $5B+ peak framing management has maintained since the Intra-Cellular acquisition, and the +122% new-patient-start metric is a leading indicator that the reported +70.9% understates. Neuroscience gets almost no airtime in the JNJ debate and is compounding at a mid-teens rate.

Segment Performance — MedTech ($8.93B, +3.6% operational)

The segment decelerated from +4.6% operational in Q1 and missed consensus, the only line in the print to do so. It is also the segment on which we set an explicit test in April: the compression case becomes load-bearing if Q2 does not accelerate. It did not. But the decomposition matters enormously, because the deceleration is not broad. Three of four businesses accelerated and beat management's internal expectations. One business, cardiovascular, broke.

Cardiovascular

In April we wrote that cardiovascular "is doing the work" while surgery and orthopaedics carried the drag. The polarity reversed completely this quarter. Cardiovascular grew 3.1% and was the only MedTech business to decelerate, while surgery, vision and orthopaedics all accelerated. Within it, Shockwave remains excellent at +14.7% with the C2 Aero global launch adding coronary reach. Electrophysiology at +3.1% is a China destocking artifact more than a demand signal; management sized the inventory impact at 400bps, which would put underlying growth north of 7%, though competitive PFA pressure is also acknowledged and is not going away. The VARIPULSE platform now has more than 85,000 AFib patients treated worldwide, CARTOSOUND SONATA debuted, and the dual-energy THERMOCOOL SMARTTOUCH SF received FDA authorization, so the product cadence is intact even as the print is not.

Assessment: The EP issue is almost certainly transitory and we would not change a model over it. Abiomed is a different matter, and it is the subject of the most important exchange on the call. We treat cardiovascular as a pillar that has moved from confirming the thesis to needing to prove it, which is exactly the status change that costs a rating notch when the stock is at 21x.

Surgery, vision and orthopaedics

All three accelerated, which is the part of the print the tape ignored. Surgery went to +2.3% from +1.2% on wound closure and near-double-digit biosurgery growth, absorbing 40bps of divestiture drag plus continuing China VBP and competitive pressure in energy and endocutters. Vision accelerated to +5.6% with contact lenses more than doubling their Q1 rate to +6.0%; U.S. surgical vision remains negative at -6.0% on TECNIS competitive entrants, but PureSee is now expanding in the U.S. and is the reversal catalyst we flagged in April. Orthopaedics went to +4.2% from +3.2% on the VOLT trauma launch, with trauma at +6.9% and knees at +5.0%, and it did so while running a separation process, which is not the usual pattern for a business being carved out.

Assessment: This is the quietly encouraging half of MedTech and it validates the "seasonal not structural" framing we accepted on the Q1 print. Orthopaedics improving into a mid-2027 separation is a genuine positive for the eventual transaction value. If cardiovascular had merely held its Q1 rate, MedTech would have printed above 5% and this recap would have a different rating on it.

Key Topics & Management Commentary

Overall Management Tone: Confident on Innovative Medicine and unusually forthcoming on the MedTech shortfall, which management raised, named and quantified before any analyst could. The posture on cardiovascular was concessive rather than defensive, an improvement on the deflection we would have expected a year ago, but the concession came with a recovery timeline that two executives described differently within twenty minutes of each other and that no one reconciled. Tone was the most assured we have heard on the launch portfolio and the least precise we have heard on when a broken business gets fixed.

1. Abiomed: a 300-patient trial resets a $2B franchise

The single most consequential disclosure in the print. Abiomed declined 2% after growing 14% in Q1, and the cause is neither demand nor reimbursement nor competition. It is a neutral clinical trial published in the U.K. covering roughly 300 patients in high-risk PCI, which made physicians more selective about Impella almost immediately. Management's evidentiary rebuttal is strong on the merits: Impella has supported more than 400,000 patients, appears in roughly 2,600 peer-reviewed publications, and J&J has studied more than 40,000 high-risk PCI patients against the U.K. study's 300.

"I think it's important, firstly, to really reinforce that the impact is behavioral. It's really driven by physician caution as they interpret this new data rather than anything structural, and there's no change in the underlying need, access or reimbursement. These are the sickest patients, many of whom have very few choices. So we clearly see this as a near-term dynamic." — Tim Schmid, EVP & Worldwide Chairman, MedTech

The confirmatory study is PROTECT IV, powered at nearly 1,300 patients and specifically focused on high-risk PCI. It reads out in 2027. That date is the problem. Management is asking the market to hold a franchise at a depressed growth rate for eighteen months on the strength of evidence that already exists but is evidently not persuading the physicians who matter.

Assessment: We accept that the mechanism is behavioral. We do not accept that behavioral means brief. Abiomed pioneered heart pumps and remains the only player in the category, which management frames as a moat; it is also a structural weakness in this particular situation, because a category with a single vendor has no independent voice to defend it, and physician caution in the absence of a competing narrative tends to harden into practice pattern. The right way to hold this is as a real reset with a 2027 catalyst, not a one-quarter air pocket.

2. The recovery timeline management did not reconcile

Two executives gave materially different answers on when Abiomed recovers, in the same call, and neither was pressed on the gap. The CFO's version, offered early in response to the guidance question, sets a floor of modest growth persisting until the 2027 data. The MedTech chairman's version, offered later, promises a return to double digits within "coming quarters."

"We have tempered expectations around the Abiomed business with respect to that. We see that recovery happening, but probably as we leave this year into next year. Not declines, but more modest growth until our PROTECT IV data comes out." — Joe Wolk, CFO

"To your question around recovery, as already mentioned by Joe, we do expect this to take some time, but we absolutely expect that our performance in the back half will be stronger than the first, and we see gradual improvements in performance back to double-digit growth over the coming quarters." — Tim Schmid, EVP & Worldwide Chairman, MedTech

These cannot both be true. If Abiomed is at modest growth until PROTECT IV reads out in 2027, it is not returning to double digits "over the coming quarters." Schmid frames his answer as agreeing with Wolk ("as already mentioned by Joe"), which obscures rather than resolves the difference.

Assessment: We weight the CFO's version, because CFOs guide and segment heads sell, and because Wolk's version is the one embedded in a guide he has to hit. The practical read is that Abiomed contributes roughly nothing to MedTech growth for the next several quarters, which mechanically caps MedTech in the low-to-mid single digits regardless of how well surgery, vision and orthopaedics execute. That is the specific reason we can no longer underwrite the MedTech re-acceleration pillar at an Outperform-justifying multiple.

3. ICOTYDE: the launch is now a fact, not a hope

At Q1 we called ICOTYDE the single most important data point in the print at roughly 1,500 prescriptions and 1,000 prescribers. One quarter later the numbers are 18,000 prescriptions written across 11,000 patients, with 6,000 unique prescribers, up from 4,500 as recently as June. The composition is the interesting part: more than 50% of writers are advanced practice professionals, about 40% are dermatologists, and the balance are primary care and others.

"To date, over 18,000 prescriptions have been written for a total of now 11,000 patients. There are 6,000 unique prescribers, and if you take a look at those, over 50% are actually advanced practice professionals. About 40% are dermatologists, and the rest are primary care physicians and others… As we take a look at the payer coverage, within 90 days, we already have over 50% of commercial coverage, we think that's great. That's actually a little bit ahead of our expectations." — Jennifer Taubert, EVP & Worldwide Chairman, Innovative Medicine

Two things de-risked simultaneously. The payer question, which was our stated Q1 watch item, resolved ahead of plan at over 50% commercial coverage inside 90 days. And the prescriber-mix question resolved in favor of market expansion rather than share-shifting: advanced practice professionals and primary care physicians are not the people who were already writing biologics. Direct-to-consumer advertising began the day before the call.

Assessment: This is the strongest launch evidence we have seen from this company and it substantially supports the "one of our largest products ever" framing. It also raises our fair value, because a de-risked ICOTYDE is worth more multiple than a hoped-for one. What it does not do is make the stock cheap at 21x, because the market has been watching the same metrics.

4. ICOTYDE and TREMFYA: no cannibalization, so far

The obvious bear question on ICOTYDE is whether J&J is selling a $10B biologic's patients an oral pill at a lower price. Management's answer is a clean segmentation, and this quarter's numbers support it: TREMFYA grew 71% in the same quarter ICOTYDE reached 11,000 patients.

"You asked about ICOTYDE and TREMFYA, and I think really important to note, we've got this great uptick in ICOTYDE. This has not slowed down TREMFYA in psoriatic disease at all… ICOTYDE is the first-choice systemic treatment. All those patients who've been cycling on topicals who really need to have advanced therapy, we think ICOTYDE fits right in that sweet spot as that first-choice systemic. For TREMFYA, we think it's the first-choice biologic, particularly for patients that have potential for or have any psoriatic arthritis involvement." — Jennifer Taubert, EVP & Worldwide Chairman, Innovative Medicine

Assessment: The segmentation is coherent and the prescriber mix is the hard evidence for it. The honest caveat is that early launches always look non-cannibalizing, because the first patients through the door are the easy ones who were not on anything. The real test comes when the topical-cycling pool is worked through, which is a 2027 question. For now, both products growing simultaneously is exactly what the bull case needs and it is what printed.

5. INLEXZO compounds, but the disclosure does not

Every operating metric improved. One in three eligible patients now start on an INLEXZO regimen, up from one in four at Q1. New patient insertions grew approximately 75% sequentially post-J-code. NCCN guidelines carry a Category 2A designation and were expanded to include the papillary population, roughly 80% of BCG-unresponsive patients. Management says sales more than doubled sequentially off a Q1 base of just over $30M, implying something north of $60M, and that it beat consensus.

"While we don't report sales on this yet, please know that we confidently beat consensus for the quarter, and we more than doubled sales in the second quarter versus the first quarter." — Jennifer Taubert, EVP & Worldwide Chairman, Innovative Medicine

The addressable-population ladder management laid out is the reason to care: the current SunRISe-1 approval addresses roughly 3,000 U.S. patients in the BCG-unresponsive setting, of which the CIS population is only about 5% of the eligible pool; SunRISe-5 in BCG-experienced patients addresses 10,000–15,000; and SunRISe-3 in BCG-naive patients addresses 40,000–50,000. Behind all of it sits the drug-releasing device with erdafitinib, offering three months of sustained delivery against INLEXZO's three weeks.

Assessment: The commercial unlock we identified at Q1 is playing out and the ladder above it is large enough to matter to the 2030 framing. But claiming a consensus beat on a product with no disclosed sales is a rhetorical move, not a disclosure, and this is now the third quarter of launch without a line item. We would like the number.

6. STELARA: the trough is confirmed and behind us

The most important number nobody discussed. STELARA declined 55.7% operationally, an improvement on Q1's 61.7%, and grew 12.8% sequentially, from roughly $656M to $740M. The enterprise drag narrowed from 540bps to 460bps and the Innovative Medicine drag from 920bps to 760bps.

"It's also worth noting, STELARA was only 4% of our Innovative Medicine business in the second quarter. If you exclude that, the 96% of our business actually grew over 14%." — Jennifer Taubert, EVP & Worldwide Chairman, Innovative Medicine

Assessment: We called Q1 the modelled trough. It was. The sequential increase is the confirmation, and at 4.5% of Innovative Medicine there is very little absolute dollar left to lose. This pillar is now effectively resolved and should be retired from the debate. The corollary is that the ex-STELARA growth rate stops being an adjustment and starts being the reported rate over the next several quarters, which is the mechanical reason the 2027 acceleration story has arithmetic behind it.

7. The margin guide goes up while the first half ran down

Management raised the full-year adjusted pre-tax operating margin guide to approximately +75bps from "more than 50bps." That cleared our Q1 downgrade trigger and it did so while absorbing two acknowledged costs: the 53rd week of operations and the previously announced agreement with the U.S. government on drug pricing.

"At the beginning of the year, we guided to more than a 50 basis point improvement in the adjusted pre-tax operating margin. We now expect approximately a 75 basis point improvement, supported by continuing operating efficiencies and anticipated reduction and recoupment of certain tariff-related costs based on the latest rulings." — Joe Wolk, CFO

The arithmetic underneath deserves attention. On the reported adjusted pre-tax income margin, the closest disclosed proxy, H1 2026 ran 33.4% against 35.5% in H1 2025, a decline of 212bps. To average roughly +75bps for the full year from that starting point, the second half has to run on the order of 300 to 350bps better than prior-year H2 on our math. That is not a rounding adjustment; it is the entire margin story compressed into two quarters. And the composition of the raise is not purely operational: "anticipated reduction and recoupment of certain tariff-related costs based on the latest rulings" is a legal and regulatory recovery, real cash but non-recurring, and it sits alongside unquantified "operating efficiencies."

Assessment: We give management credit for the direction and for the Q2 print that earned it. But an H2 swing of that magnitude, guided upward while ICOTYDE direct-to-consumer advertising is just starting and R&D expense phasing pushes spend into the same half, is the single largest execution risk in the FY26 guide. It is also the reason we treat the margin pillar as confirmed rather than resolved.

8. The second-half acceleration is mostly the calendar

Management guided to improving operational sales growth in H2, with Q4 higher on the 53rd week. The guide's own midpoint says something more restrained. H1 adjusted operational growth was 5.5%; the full-year adjusted operational guide midpoint is 6.5%, implying H2 at roughly 7.4%. The 53rd week is worth approximately 100bps on the full year, and because it lands entirely in Q4 it is worth roughly 195bps on the half. Strip it out and the implied H2 underlying rate is about 5.5%, the same as H1. On the operational (rather than adjusted operational) basis the picture is similar, with implied H2 underlying growth of roughly 5.6% against H1's 6.0%.

"As we look at the remainder of the year, based on year-to-date performance and updated guidance, we anticipate operational sales growth to improve in the second half of the year. As a reminder, fourth quarter growth should be higher due to the benefit from the 53rd week." — Joe Wolk, CFO

Assessment: The statement is technically accurate and the implication is generous. At the top of the guided range there is roughly 20bps of genuine underlying H2 acceleration; at the midpoint there is none. The fair caveat is that JNJ guides conservatively and has beaten its own guide each quarter this year, so the implied H2 is a floor rather than a forecast. But investors underwriting "second-half acceleration" should know that on the company's own midpoint, the acceleration is the extra week.

9. Procedure volumes: management pre-empts the sector fear

Large U.S. hospital operators flagged elective-procedure pressure the same week as this print, and the MedTech miss landed into a market already primed to read a demand slowdown. Management addressed it unprompted and unusually directly, on both the hospital data and the separate question of ACA subsidy expiry.

"We are acutely aware of the recent data that has been provided by a number of large U.S. hospital operators, highlighting pressure on certain procedure volumes, particularly in more elective areas of care. While we're monitoring these trends very closely, they are not reflected in what we're seeing across our portfolio today… To be clear, we would not attribute our MedTech performance in Q2 to a systemic slowdown in procedures." — Tim Schmid, EVP & Worldwide Chairman, MedTech

Assessment: This is the right disclosure and it is credible, because it is self-incriminating. Management is explicitly declining the available excuse. If procedures were soft, the MedTech miss would be macro and forgivable; by ruling it out, management owns the shortfall as company-specific and executable. That is a mark of candour, and it is also why the miss should be read as a genuine reset of the cardiovascular growth rate rather than a market event that mean-reverts on its own.

10. The double-digit bridge and the December 8 review

The long-term framing was reasserted with more specificity than usual: 28 platforms each generating more than $1B in annual revenue, an ambition to be the number one oncology company by 2030 with sales exceeding $50B, and robotics contributing meaningfully by the end of the decade. Management continues to insist the bridge does not require M&A.

"When I look at our top-line growth, the momentum that we are going to carry into the second half of the year into 2027, our ambition to have double-digit growth by the end of the decade, the operating leverage that that sustained top-line growth is going to create. I see Johnson & Johnson, when I consider those factors, as one of the most compelling and transparent growth stories in healthcare today." — Joaquin Duato, Chairman & CEO

Assessment: The word doing the work in that sentence is "transparent," and it is the one thing the framework is not yet. Double-digit-by-end-of-decade has been asserted for four consecutive quarters without a quantified bridge, a base year, or a definition of which line it applies to. The December 8 Enterprise Business Review is where that gets numbers attached, and it is the most valuable scheduled catalyst in the story. It is also, at 21x, the thing the current price arguably already assumes.

11. Capital allocation: the cash snapped back

Q1's light free cash flow was the one balance-sheet blemish we carried forward, and it reversed. H1 free cash flow reached approximately $8.7B against $6.2B in the prior-year period, and the company reaffirmed a full-year outlook approaching $21B. Cash and marketable securities stand at roughly $21B against roughly $49B of debt, a net debt position of roughly $28B, improved from roughly $33B at Q1. The Firefly Bio acquisition, adding a degrader-antibody-conjugate platform aimed at KRAS-driven solid tumors, is expected to close in Q3 and is not in the guide.

"As stated previously, acquisitions are an enabler of growth, but they are not a requirement to deliver on our near and long-term objectives." — Joe Wolk, CFO

Assessment: The FCF recovery removes a live question and the deleveraging is meaningful at this scale. Firefly is a small platform tuck-in consistent with the stated sweet spot, and excluding pending deals from guidance is the conservative treatment. Nothing here changes the thesis; everything here supports the balance-sheet quality that underpins the dividend.

12. DePuy Synthes: still "all options," still mid-2027

The orthopaedics separation is progressing on the operating line, with the business accelerating to +4.2%, and the structure remains deliberately unspecified. Management appointed a CFO for the standalone entity this quarter, which is the kind of concrete step that usually precedes a structure decision.

"We continue to evaluate all separation options that create shareholder value and set the DePuy Synthes business up for success long term. We are pleased with the progress made, are on track for a mid-2027 separation, and look forward to sharing updates later this year." — Joe Wolk, CFO

Assessment: Identical language to Q1, which we read as the structure genuinely still being open rather than decided and withheld. The CFO appointment and the operating improvement both raise the eventual value of whatever vehicle is chosen. "Updates later this year" points at the December 8 review. We keep the mix-lift in the model and continue to treat the structure as the variable.

Guidance & Outlook

This is a real raise and a materially bigger one than April's. The $0.18 adjusted operational EPS increase is nine times Q1's $0.02, and the fact that the reported raise is only $0.13 is a currency artifact rather than a hedge: the euro moved from 1.17 to 1.14 and took $0.05 back. Both the sales range and the EPS range narrowed while the midpoints rose, which is the signature of a management team that has genuinely gained visibility rather than one buying optionality. Firefly Bio is excluded, so any accretion or dilution is incremental.

Implied H2 ramp: On the adjusted operational basis, H1 delivered 5.5% and the FY midpoint of 6.5% implies H2 at roughly 7.4%. Approximately 195bps of that is the 53rd week landing in Q4, leaving implied underlying H2 growth of roughly 5.5%, level with H1. On margin the ramp is far more demanding: H1 ran 212bps below prior year on the adjusted pre-tax income margin, so an FY outcome of +75bps requires an H2 swing on the order of 300 to 350bps.

Street at: Consensus entering the print sat at roughly $2.85 adjusted EPS and $25.05B revenue, both of which the company cleared. The FY26 midpoint of $11.68 now sits above where consensus had been anchored at the April guide of $11.55, so the Street's FY numbers move up. The segment split is where consensus was wrong in both directions: Innovative Medicine beat a ~$16.1B estimate by roughly $280M, and MedTech missed ~$8.97B by roughly $40M. Given the tape's reaction, the MedTech line is the one the Street was actually underwriting.

Guidance style: Consistently conservative and consistently beaten. This management team has raised in each of the last three quarters and has not yet set a bar it failed to clear. That history argues the implied H2 numbers above are floors rather than forecasts, and it is the strongest single argument against our own margin scepticism. It is not, however, an argument for paying 21x.

Analyst Q&A Highlights

The composition of the guidance raise

The opening question went straight to the structure of the $400M operational sales increase, asking whether the right mental model is pharma moving higher partially offset by lower MedTech assumptions. The answer confirmed it without hesitation and volunteered more than was asked, including the first explicit statement that Abiomed expectations had been cut and that the recovery runs past this year.

Q: "Maybe just, Joe, if you could dive a little bit more into the $400 million increase in operational sales guidance… is it fair to think about pharma moving higher here, maybe partially offset by a bit lower MedTech growth assumptions?"
— Chris Schott, J.P. Morgan

A: "I would say that's probably a fair characterization… we do expect MedTech to grow better in the second half than the first half as well. We have tempered expectations around the Abiomed business with respect to that. We see that recovery happening, but probably as we leave this year into next year. Not declines, but more modest growth until our PROTECT IV data comes out."
— Joe Wolk, CFO

Assessment: The most valuable ninety seconds of the call, and it happened first. Management conceded in the opening answer that the raise is pharma carrying MedTech, and that Abiomed is impaired until 2027 data. Everything said later about a faster cardiovascular recovery has to be read against this, because this is the version that the guide is built on.

ICOTYDE launch metrics and the payer question

A multi-part question pressed on prescriber count, sampling and free drug, formulary progress, and when sales get broken out. The response delivered on three of four, with detail well beyond what was asked, and quietly declined the disclosure question.

Q: "Just wondering if you can provide any update on prescriber count relative to the last update of 4,500 prescribers that you called out in June. What can you tell us about sampling and free drugs that you're providing and where you are with formulary negotiations? When can we expect to see you break out sales?"
— Asad Haider, Goldman Sachs

A: "To date, over 18,000 prescriptions have been written for a total of now 11,000 patients. There are 6,000 unique prescribers… As we take a look at the payer coverage, within 90 days, we already have over 50% of commercial coverage… That's actually a little bit ahead of our expectations."
— Jennifer Taubert, EVP & Worldwide Chairman, Innovative Medicine

Assessment: Prescribers moved from 4,500 in June to 6,000 by the call, which is a steeper slope than the quarterly numbers alone convey. Payer coverage above 50% inside 90 days resolves our stated Q1 watch item ahead of schedule. The sampling and free-drug question went unanswered, which matters because gross-to-net on a first-year oral launch determines whether 11,000 patients is a revenue event or a trial event. Nobody followed up.

Abiomed's new growth rate

The most pointed exchange on the call, and the only one where an analyst explicitly noted that the prior expectation was mid-teens growth and asked for the replacement number. No number was given. The response instead re-litigated the evidence base and offered a qualitative recovery path that contradicted the CFO's earlier framing.

Q: "I'm still just a little unclear as to what you're doing to reverse the 2Q softness outside of just waiting for PROTECT IV. I think prior view was this was a mid-teens grower. What is the new growth expectation for the Abiomed business?"
— Jayson Bedford, Raymond James

A: "We've seen this before, and we are actively engaging with physicians and their teams to really reinforce appropriate patient selection… we do expect this to take some time, but we absolutely expect that our performance in the back half will be stronger than the first, and we see gradual improvements in performance back to double-digit growth over the coming quarters."
— Tim Schmid, EVP & Worldwide Chairman, MedTech

Assessment: The question asked for a number and got a trajectory, and the trajectory conflicts with the CFO's "modest growth until PROTECT IV." A franchise that just went from +14% to -2% and whose confirmatory data is eighteen months out does not have a knowable growth rate right now, and saying so would have been more credible than "double-digit over the coming quarters." This exchange is the single largest reason the MedTech pillar moves to at-risk in our scorecard.

Procedure volumes and the second-half MedTech bridge

A recurring line of questioning on whether U.S. procedure growth is slowing, sharpened by hospital-operator commentary published the same week, and whether MedTech still grows faster in 2026 excluding the extra week. The answer decisively separated the company-specific issue from the macro one and, in doing so, declined an available excuse.

Q: "Tim, I'm sure you know there continue to be concerns about procedure growth in the U.S. What did you see in Q2, and how are you thinking about procedure growth the rest of the year?… Do you still expect MedTech to grow faster in 2026, excluding the extra week?"
— Larry Biegelsen, Wells Fargo

A: "To be clear, Larry, three of our four businesses—surgery, vision, and orthopedics—all accelerated in the quarter and performed above expectations… let me first acknowledge that our Q2 growth is not where you wanted it, and frankly, it's not where we wanted it. That said, we know what happened, and we know exactly what we're doing about it."
— Tim Schmid, EVP & Worldwide Chairman, MedTech

Assessment: The acknowledgement is genuine and the three-of-four framing is verifiable against the disclosed subsegment growth rates. But the direct question, whether MedTech still grows faster in 2026 excluding the 53rd week, was not answered. That omission is conspicuous given the implied-H2 arithmetic, and it is consistent with a guide whose acceleration is more calendar than operations.

INLEXZO utilization and the SunRISe expansion ladder

A question seeking utilization detail by care setting, patient type, and prescriber count, plus expectations for the SunRISe-5 readout. The response substituted a population ladder for the requested granularity, which turned out to be the more useful answer.

Q: "Maybe you can just give a little more color on where you're seeing utilization to differentiate between the community setting, academic setting, what sorts of patients are getting the products? I do not know if you can share anything around patient numbers or prescriber numbers."
— Vamil Divan, Guggenheim Securities

A: "1 in 3 eligible patients are now starting on an INLEXZO regimen. This is an uptick versus the first quarter, where it was one in four… In terms of new patients and new patient insertions, those grew 75% quarter-over-quarter, and this was post the permanent J-code… While we don't report sales on this yet, please know that we confidently beat consensus for the quarter."
— Jennifer Taubert, EVP & Worldwide Chairman, Innovative Medicine

Assessment: Share of eligible patients rising from one in four to one in three in a single quarter is a strong penetration signal and the 75% insertion growth confirms the J-code unlock we identified in April. The setting-level detail requested was not provided, and the consensus-beat claim is unfalsifiable on an undisclosed product. Three quarters into launch, the absence of a line item is starting to be the story.

milvexian timing and the AFib readout

A question on confidence in the atrial fibrillation indication and whether the trial remains on track for this year, noting its absence from the slide deck. The answer was candid about the limits of what management can know.

Q: "Can you remind us of your confidence level in AFib? I guess given the size and breadth of the milvexian program, it seems like there's potentially a wide set of outcomes between a clean win and miss. Is the trial still on track for later this year? I did not see it on the slide deck."
— Alex Hammond, Wolfe Research

A: "These are event-driven studies. They're fully recruited. We really can't give you very much insight into when they might read out. Could be towards the end of this year, beginning of next year, but because they're event driven, we'll just have to wait for the events… Our data monitoring committee continues to look at the data. They keep saying, 'Go full steam ahead.'"
— John Reed, EVP, Innovative Medicine Research and Development

Assessment: The right answer, given honestly, including the implicit confirmation that the slide-deck omission reflects genuine timing uncertainty rather than a problem. The market opportunity framing is the part worth carrying: roughly eight million Americans take an oral anticoagulant against an estimated eighteen million who should, with bleeding risk the binding constraint. We carry milvexian as a free option, unmodelled. A clean AFib win is the largest single upside not in anyone's numbers, including ours.

TREMFYA versus the competing IL-23 in IBD

The closing question asked why the principal competitor is holding share in gastroenterology despite TREMFYA's apparent profile advantage. The answer reframed the premise with induction-share data rather than accepting it.

Q: "In GI, TREMFYA seems to have an edge over SKYRIZI, yet SKYRIZI is holding its own. My question is, to what do you attribute SKYRIZI's ability to hold share?"
— Mike Nolkovich, TD Cowen

A: "If you take a look at new patient starts or induction share in both ulcerative colitis and Crohn's disease, we currently are the share leader in both. For example, in ulcerative colitis, 58% share of induction or induction share for the IL-23s… As a reminder, back when we had STELARA here, over 75% of STELARA sales were actually in IBD. There is absolutely no reason why TREMFYA can't do that or even more."
— Jennifer Taubert, EVP & Worldwide Chairman, Innovative Medicine

Assessment: The distinction between total share and induction share is the whole answer, and it is the right one: induction share is the leading indicator, total share is the lagging one, and a 58% induction share in ulcerative colitis converts into total share over the following years as the installed base turns over. The STELARA-was-75%-IBD comparison is the most useful sizing anchor management has offered for TREMFYA's peak, and it implies a number above the $10B we currently carry.

What They're NOT Saying

1. The Abiomed recovery timeline, reconciled. The CFO said modest growth until PROTECT IV, which reads out in 2027. The MedTech chairman said double-digit growth over the coming quarters. Both statements were made on this call, roughly twenty minutes apart, and the second was framed as agreeing with the first. No analyst reconciled them and management did not volunteer which is operative. The guide implies the CFO's version.
2. Abiomed's actual growth expectation. Asked directly and explicitly for the replacement number after a mid-teens prior view, management gave a trajectory and an evidence recitation. No number for Q3, no number for FY26, no number for the recovery year.
3. Whether MedTech still grows faster in 2026 excluding the 53rd week. Asked directly. Not answered. Given that the implied H2 underlying sales growth for the enterprise is level with H1 once the extra week is stripped, this omission is doing work.
4. Where the 300-to-350bps H2 margin swing comes from. The guide went up while H1 ran 212bps down. The named sources are "continuing operating efficiencies," which is unquantified, and tariff recoupment "based on the latest rulings," which is exogenous and non-recurring. Meanwhile ICOTYDE direct-to-consumer advertising launched the day before the call and R&D expense phasing pushes spend into the same half. Nobody asked how the bridge closes.
5. Talc and Daubert: a second consecutive quarter of total silence, but the accrual is rising. Not one question, not one word in prepared remarks. At Q1 we read the silence as constructive. It reads differently now, because the litigation line moved: the pre-tax litigation adjustment was $267M this quarter against $57M a year ago, and $597M for the half. Management attributed higher other expense partly to "higher litigation expense." The substantive Daubert ruling was expected "by 2026" as of our Q3 2025 upgrade; we are past the midpoint of 2026 with no update and no one asking. Rising cost with falling disclosure is not the same thing as resolution.
6. INLEXZO's sales, for a third straight quarter. Management claims a consensus beat on a product it does not report. There is no published consensus for an undisclosed line item, so the claim cannot be checked. The disclosure is now lagging the product's materiality.
7. ICOTYDE gross-to-net, sampling and free drug. Explicitly asked, entirely unaddressed. 11,000 patients is the headline; how many are paid is the number that determines what the launch is worth in 2026.
8. The duration of the China electrophysiology inventory dynamic. Sized precisely at 400bps for the quarter and given no forward shape. A one-quarter destock and a multi-quarter channel reset look identical in a single print.
9. MedTech's segment margin, which never actually recovered. At 22.0% it is essentially where it was a year ago at 22.2%, and far from the 25.7% that preceded the compression we flagged at initiation. The "MedTech margin recovery" has been part of the bull case since Q3 2025 and has not appeared in the segment margin line.

Market Reaction

• Pre-print setup: Closed at $253.85 on July 14, entering the print +22.7% year-to-date against the S&P 500's +10.2%, +7.7% over the trailing 30 days and +63.6% over the trailing twelve months. The 52-week closing range was $155.17 to $267.24, so the stock came in roughly 5% below its high and near the top of a range it had doubled through.
• Reaction session (before-open reporter, reaction is the print day): Opened $248.76, a 2.0% gap down, traded between $246.10 and $256.83, and closed at $247.02, down 2.7% or $6.83, near the low of the day. The brief push to $256.83 was sold.
• Volume: 10.0M shares against an 8.6M 30-day average, 1.2x normal. Elevated but not capitulatory.
• Relative: The S&P 500 rose 0.4% on the session, so JNJ underperformed the index by roughly 310bps on a day it beat on revenue, beat on EPS, and raised full-year guidance twice over.

A 2.7% decline on a beat-and-raise is not a verdict on the quarter. It is a verdict on the setup. Three forces combined, and it is worth separating them because they have very different half-lives.

The proximate cause is the MedTech line. It was the only number in the print that missed, and it missed by roughly $40M on $8.97B, which is a rounding error in isolation and a signal in context. The context is that MedTech is the segment carrying the 2030 re-acceleration story, cardiovascular is the business that was supposed to carry MedTech, and cardiovascular is what broke. A market that had been paying for MedTech acceleration got MedTech deceleration, and the fact that the enterprise beat anyway is precisely the point management made and the market declined to reward.

The second force is positioning, and it is the one we weight most heavily. A stock up 63.6% over twelve months and 22.7% year-to-date against a +10.2% index has consumed its own good news. At that setup a beat is the entry ticket rather than the catalyst, and any blemish gets the full weight of the move. The intraday path supports this reading: the stock traded up to $256.83 at one point, above the prior close, and finished near its low. Someone used the strength to sell.

The third force is sector, and it is largely noise. Large hospital operators had flagged elective-procedure pressure the same week, priming the market to read any device softness as a demand slowdown. Management pre-empted this directly and, in our view, credibly, explicitly declining to attribute the MedTech shortfall to procedure volumes. The market appears to have discounted the disclaimer along with the guide.

Street Perspective

Debate: Is the Abiomed decline behavioral or structural?

Bull view: A single 300-patient neutral trial cannot overturn an evidence base of 40,000 studied high-risk PCI patients, 400,000 patients supported, and roughly 2,600 peer-reviewed publications. There is no competitor, no reimbursement change and no demand change. Physician caution mean-reverts as the field re-reads the data, and PROTECT IV settles it definitively.

Bear view: PROTECT IV does not read out until 2027, and until it does the most recent data point in the literature is unfavourable. A single-vendor category has no independent advocate, so there is nobody but the manufacturer to make the counter-argument, which is the weakest possible position from which to make it. Behavioral shifts in device utilization have a way of hardening into practice patterns and then into guidelines.

Our take: The bull has the better evidence and the worse clock. We think management is probably right on the science and probably optimistic on the timing, and for an equity holder the timing is what gets paid. The CFO's own framing, modest growth until 2027 data, is the operative one, and it means Abiomed contributes approximately nothing to MedTech growth for several quarters. Behavioral is not the same as brief.

Debate: Is the margin guide raise operating leverage or tariff accounting?

Bull view: Raising to +75bps from +50bps while simultaneously absorbing 53rd-week operating costs and the U.S. government pricing agreement is an unambiguous signal of underlying leverage. Gross margin expanded 30bps in the quarter despite MedTech tariffs. Management has beaten every bar it set this year.

Bear view: H1 ran 212bps below prior year, so the entire full-year improvement is an H2 event requiring a swing on the order of 300 to 350bps. Management named tariff recoupment "based on the latest rulings" as a source, which is a legal recovery rather than operating leverage, non-recurring by construction and dependent on rulings outside the company's control. The rest is "operating efficiencies," unquantified.

Our take: Both, and the mix is the question nobody asked. We are comfortable that the Q2 print earned the raise and that the direction is right. We are not comfortable underwriting a 300bps-plus H2 swing at a 21x multiple, particularly with ICOTYDE direct-to-consumer spend just beginning and R&D phasing pushing expense into the same half. The guidance-conservatism history is the strongest argument against us here, and it is a good argument.

Debate: Is ICOTYDE expanding the market or cannibalizing TREMFYA?

Bull view: TREMFYA grew 71% in the same quarter ICOTYDE reached 11,000 patients, which settles the question empirically. The prescriber mix settles it structurally: over half of ICOTYDE writers are advanced practice professionals and a further share are primary care physicians, neither of whom were writing biologics before. The company is reaching the 70–80% of biologic-eligible autoimmune patients who are on nothing.

Bear view: Every launch looks non-cannibalizing in its first two quarters, because the initial patients are the easy ones who were untreated. The overlap test comes when the topical-cycling pool is exhausted and the next marginal ICOTYDE patient is someone who would otherwise have started a biologic, at a lower price point.

Our take: The prescriber mix is the strongest evidence available and it favours market expansion, decisively enough that we treat this pillar as confirmed. The bear point is real but is a 2027 question, and by then psoriatic-arthritis and IBD data should have expanded the label into indications where the two products genuinely do not compete. This is the one debate where we think the bulls are simply right.

Debate: Has the multiple gotten ahead of the compounding?

Bull view: This is no longer a pharma company trading on a pharma multiple. It is 28 platforms each above $1B, the best pipeline in a 140-year history, a line of sight to double-digit growth by decade end, the number one oncology franchise by 2030 at $50B-plus, and a launch portfolio inflecting faster than internal models. Growth like that deserves a growth multiple, and the December 8 review is where the market learns to underwrite it.

Bear view: 21.1x is a full price for a business guiding to roughly 7% operational sales growth and 7–8% adjusted EPS growth, where the growth segment just decelerated, the margin story is entirely second-half, and part of the EPS raise is tax and interest. The stock is up 63.6% in twelve months. Double-digit-by-decade-end has been asserted for four quarters without a quantified bridge.

Our take: This is the debate that decides the rating and we come down with the bears, narrowly and without enthusiasm. The bull case is not wrong about the business; we raised fair value because we think it is substantially right. It is wrong about the entry point. At 21.1x, twelve months of good execution is already paid for, and the two things that would justify more, the H2 margin ramp and the cardiovascular recovery, are precisely the two things this quarter made less certain rather than more.

Model Update Needed

Valuation impact: Fair value range raised to $215–245 from $190–220, equivalent to 18.4–21.0x the FY26 adjusted EPS guide midpoint of $11.68, up from the 17–19x framework carried since the Q3 2025 upgrade. The multiple expansion is deliberate and reflects genuinely better earnings quality: a raised margin guide, a de-risked ICOTYDE launch, a lower tax rate, improved net debt and a confirmed STELARA trough. At the $247.02 close the stock sits above the range midpoint by roughly 7%, and roughly 5% after the 2.1% dividend yield, which is what a Hold looks like.

Thesis Scorecard Post-Earnings

Graded against the standing thesis carried since the Q3 2025 upgrade, pillar for pillar, not a fresh set.

Overall: the operating thesis is stronger than at any point since the Q3 2025 upgrade, and the rating is coming down anyway. Five pillars confirmed or reinforced, one challenged, two neutral, and one new bear point that is now the binding constraint. That is not a contradiction; it is the whole point. We upgraded in October 2025 because a good business was priced as a legacy pharma. Nine months and 63.6% later, the business is better than we underwrote and the price is no longer the reason to own it. The margin bear point that would have triggered a downgrade at Q1 has receded; the valuation bear point that replaced it is the one doing the work.

Action: Hold. Do not add at 21.1x. Existing holders have no fundamental reason to exit, and the dividend, balance sheet and launch cadence all argue for patience rather than sale. We would return to Outperform on a pullback toward the high $190s, on H2 delivering the margin ramp, on cardiovascular re-accelerating, or on the December 8 Enterprise Business Review attaching a quantified bridge and date to the double-digit framework. Any one of those restores the asymmetry. None of them is present today.